Attitudes and Unmet Needs Among Type 2 Diabetes Patients

Type 2 Diabetes Clinical Trial

Official title:

Attitudes and Unmet Needs Among Type 2 Diabetes Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05737810
• Other study ID #: DAS-7687
• Secondary ID: U1111-1286-0886
• Status: Completed
• Start date: March 27, 2023
• Est. completion date: April 17, 2023

Study information

• Verified date: May 2023
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes (T2D) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. Study participants will be recruited to complete a 15-minute self-administered online survey.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: April 17, 2023
• Est. primary completion date: April 17, 2023
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

2. Male or female, age above or equal between 18 to 65 years at the time of signing informed consent.

3. Diagnosed with T2D and currently treating T2D with at least one medication

4. Insulin user that is not using insulin pump

5. Lives in a target country

Exclusion Criteria:

1. Previous participation in this study. Participation is defined as having given informed consent in this study

2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

3. Does not meet inclusion criteria requirements

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Other:
• No treatment given
No treatment given

Locations

Country	Name	City	State
Australia	Novo Nordisk Investigational Site	Sydney
France	Novo Nordisk Investigational Site	Chartres
India	Novo Nordisk Investigational Site	Bengaluru
Korea, Republic of	Novo Nordisk Investigational Site	Seoul
Mexico	Novo Nordisk Investigational Site	Mexico City
Saudi Arabia	Novo Nordisk Investigational Site	Riyadh
United Kingdom	Novo Nordisk Investigational Site	London

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Australia,  France,  India,  Korea, Republic of,  Mexico,  Saudi Arabia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Current medication burden	Numerical; Multiple select from defined list	At the time of survey response (Day1)
Primary	Injection perceptions	Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"	At the time of survey response (Day1)
Primary	Attitudes regarding T2D overall	Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"	At the time of survey response (Day1)
Primary	Attitudes regarding T2D treatment	Likert scales for measurement of satisfaction from 1 "extremely unsatisfied" to 7 "extremely satisfied" and agreement from 1 "strongly disagree" to 7 "strongly agree"	At the time of survey response (Day1)
Primary	Attitudes regarding insulin icodec	Likert scales for measurement of likelihood from 0 "not at all likely" to 10" extremely likely" and agreement from 1 "strongly disagree" to 7 "strongly agree; Rank top 3 from defined list	At the time of survey response (Day1)